Commercialisation (VPAC)

A non-European medical device company had developed a medical device for helping patients with osteoarthritis of the knee. While it was being used in a number of private hospitals in the UK, the company hoped to expand its usage into the NHS and so needed evidence to assist in negotiations.

CASE STUDY 1

SITUATION
A non-European medical device company had developed a medical device for helping patients with osteoarthritis of the knee. While it was being used in a number of private hospitals in the UK, the company hoped to expand its usage into the NHS and so needed evidence to assist in negotiations.
SERVICE
Using available clinical trial data and publicly-available databases, a budget impact model was developed. The model allowed for estimating the potential savings at country, region and CCG levels.
RESULT
The model provided important evidence of the economic benefit of the medical device and was used extensively with NHS decision makers.

CASE STUDY 2

SITUATION
A blue chip company was working with European patient groups involved in rheumatoid arthritis (RA). As part of the support by the company, it was decided to develop a cost of illness study looking at the non-medical costs associated with RA such as lost tax revenue, time off work due to disability and early retirement, as well as social security benefits provided by the state.
SERVICE
The review provided an estimate of the impact of RA in terms of the indirect costs associated with the condition in eight European countries. This was done in three steps: a literature review of available data; creation of an Excel model which allowed the use of local data; a written report and presentation of the results to a meeting of European patient groups.
RESULT
The report and presentation was used extensively by the patient groups to highlight the generally low level of support for patients with RA.